Ireland Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports

Ireland Pharmaceuticals and Healthcare Report

Ireland Pharmaceuticals and Healthcare Report - Business Monitor International - Industry Reports
Ireland Pharmaceuticals and Healthcare Report
Published Sep 24, 2016
76 pages — Published Sep 24, 2016
Price US$ 1,295.00  |  Buy this Report Now

About This Report

  
Abstract:

� Business Monitor International Ltd Page - Pharmaceutical SWOT Analysis - Continued Introduction of prescription charges will hinder market growth. Adverse economic conditions have lowered medium-term consumer spending, although this trend will continue to reverse on the back of economic growth. ...Despite exiting its bailout in December ----, Ireland will keep a lid on public healthcare spending under continuing pressure from the European Commission. The US government and the OECD s ongoing efforts to mitigate tax-saving margins obtained by multinationals that relocate overseas will reduce part of the attractiveness of Ireland for global companies. Brexit negotiations pose downside risks to the UK and the EU economic outlook, which are major export markets for Irish pharmaceuticals. ...The US government and the OECD s ongoing efforts to mitigate tax-saving margins obtained by multinationals that relocate overseas will reduce part of the attractiveness of Ireland for global companies. Brexit negotiations pose downside risks to the UK and the EU economic outlook, which are major export markets for Irish pharmaceuticals.

...Obesity boom will substantially increase the non-communicable disease burden. ...Consolidation trends within the pharmaceutical industry will continue driving interest in Irish pharmaceutical equities over the coming year. Irish pharmaceutical equities are attractive merger and acquisition targets due to favourable domestic tax regimes, attractive drug pipelines and product portfolios. Strong economic growth, an increasingly robust consumer spending story, as well as growing export demand, are set to benefit pharmaceutical production indices and overall healthcare sector growth. ...Irish pharmaceutical equities are attractive merger and acquisition targets due to favourable domestic tax regimes, attractive drug pipelines and product portfolios. Strong economic growth, an increasingly robust consumer spending story, as well as growing export demand, are set to benefit pharmaceutical production indices and overall healthcare sector growth.

...In August ----, Shire reported Q--- revenues of USD-.--bn, representing a -- y-o-y increase from Q---, reflecting the company s successful completion of its USD--bn merger with Baxalta in June ----. In July ----, Minister of Health Simon Harris stated that Ireland will bid for Dublin to become the next host of the European Medicines Agency (EMA), adding to the list of candidate cities to relocate the EMA as a consequence of the UK s vote to leave the EU. Also in July, a four-year drug savings agreement between the Irish government and the pharmaceutical industry was reached. ...In August ----, Shire reported Q--- revenues of USD-.--bn, representing a -- y-o-y increase from Q---, reflecting the company s successful completion of its USD--bn merger with Baxalta in June ----. In July ----, Minister of Health Simon Harris stated that Ireland will bid for Dublin to become the next host of the European Medicines Agency (EMA), adding to the list of candidate cities to relocate the EMA as a consequence of the UK s vote to leave the EU. Also in July, a four-year drug savings agreement between the Irish government and the pharmaceutical industry was reached. The new agreement is expected to deliver EUR---mn (USD---.-mn) in savings to ...

  
Source:
Document ID
2052-5079
Industry
Format:
PDF Adobe Acrobat
Buy Now

Business Monitor International - Industry Reports—Established in 1984, Business Monitor International is a leading online publisher of specialist business information on global emerging markets. Business Monitor's range of quarterly services covers political risk, finance, macroeconomic performance, outlook and forecast, industry sectors and the business operating environment. Each Industry Report has been researched at source, and features latest-available data covering production, sales, imports and exports; 5-year industry forecasts through end-2012; company rankings and competitive landscapes for multinational and local manufacturers and suppliers; and analysis of latest industry developments, trends and regulatory changes.

About the Author


Cite this Report

  
MLA:
Business Monitor International - Industry Reports. "Ireland Pharmaceuticals and Healthcare Report" Sep 24, 2016. Alacra Store. Dec 11, 2016. <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Ireland-Pharmaceuticals-and-Healthcare-Report-2026-1448>
  
APA:
Business Monitor International - Industry Reports. (2016). Ireland Pharmaceuticals and Healthcare Report Sep 24, 2016. New York, NY: Alacra Store. Retrieved Dec 11, 2016 from <http://www.alacrastore.com/storecontent/Business-Monitor-International-Industry-Reports/Ireland-Pharmaceuticals-and-Healthcare-Report-2026-1448>
  
US$ 1,295.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.